Review of blood-cell mitochondrial markers and biological aging (2005–2025)
This narrative review covers 68 studies from 2005–2025 on three blood-based mitochondrial markers and their links to cardiovascular disease, metabolic dysfunction, cognitive decline and mortality; the evidence is promising but still maturing. [1]
Automatic summary · not editorially reviewed
The key findings
The review examines three blood-based mitochondrial markers: mtDNA copy number in peripheral blood mononuclear cells, mitochondrial membrane potential and cell-free mitochondrial DNA in plasma. [1]
Across 68 selected studies from 2005–2025, the review evaluates each marker's associations with cardiovascular disease, metabolic dysfunction, cognitive decline and mortality. [1]
The authors propose a four-phase framework for clinical translation and say these markers cannot yet responsibly inform patient care. [1]
The source at a glance
- Study type / format
- Narrative review of 68 studies (2005–2025)
- Population / context
- People whose circulating blood cells and plasma were studied in the reviewed research on biological aging
- Summary based on
- Study abstract
- Original publication
- July 1, 2026
Three blood markers as a window on biological age
The review starts from the gap between chronological age, meaning how long a person has lived, and biological age, meaning cellular health. It focuses on mitochondria, which the source says govern energy production, oxidative stress, immune signaling and programmed cell death. The authors argue that mitochondrial changes with age can be detected in circulating blood cells, giving a minimally invasive window. They examine three markers: mitochondrial DNA copy number in peripheral blood mononuclear cells, mitochondrial membrane potential, and cell-free mitochondrial DNA in plasma.
Supporting source [1]
Associations with disease and mortality across 68 studies
Across 68 selected studies published between 2005 and 2025, the review evaluates the strength, consistency and clinical relevance of each marker. It also looks at their associations with cardiovascular disease, metabolic dysfunction, cognitive decline and mortality. These are described as associations, not as proof that mitochondrial changes cause these outcomes.
Supporting source [1]
Methodological variation and a proposed four-phase framework
The authors call the evidence promising but still maturing. Significant methodological variation across studies limits direct comparisons, and robust prospective outcome data remain limited. They propose a four-phase framework for responsible clinical translation and name needed research investments, from measurement standardization to large cohort studies and intervention trials. The source states these markers cannot yet responsibly inform patient care; the framework is a proposal, not a validated tool.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a narrative review, not a new study. Methodological variation across studies limits direct comparisons, and robust prospective outcome data remain limited. The four-phase framework is a proposal, not a validated tool.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
AlShahrani AM, Ahmad SR. · europepmc.org · July 1, 2026